Velleca Mark A. 4
4 · Black Diamond Therapeutics, Inc. · Filed Sep 18, 2023
Insider Transaction Report
Form 4
Velleca Mark A.
DirectorPRESIDENT & CEO
Transactions
- Award
Common Stock
2023-09-15$3.60/sh+5,208$18,749→ 46,522 total - Award
Stock Option (Right to Buy)
2023-09-17+1,000,000→ 1,000,000 totalExercise: $3.55Exp: 2033-09-16→ Common Stock (1,000,000 underlying)
Footnotes (3)
- [F1]These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
- [F2]The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 14, 2023.
- [F3]25% of the shares subject to this option shall vest and become exercisable on September 17, 2024, with the remainder vesting in 36 equal monthly installments thereafter.